TearLab Corporation (“TearLab” or the “company”) announced that it has received written feedback from the Food and Drug Administration (FDA) on the requirements for 510(k) clearance of its TearLab Discovery™ Platform and test card measuring the inflammatory biomarker, MMP-9. The FDA-cleared predicate chosen to establish 510k substantial equivalence measures the biomarker qualitatively, while the intended use of the TearLab Discovery MMP-9 test in the submission measures the biomarker quantitatively. The agency has requested that the company provide additional information to establish correlation to the predicate.